Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CureVac
Fierce Biotech
BioNTech buys German mRNA vaccine peer CureVac in $1.2B deal
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.
James Waldron
Jun 12, 2025 8:17am
CureVac takes a legal loss as German court invalidates patent
Dec 19, 2023 1:36pm
CureVac touts 'progress' in vaccine patent case against BioNTech
Sep 28, 2023 2:45pm
CureVac expands COVID-19 patent cases against Pfizer, BioNTech
Jul 13, 2023 11:36am
Pfizer and BioNTech contest CureVac COVID shot patent charges
Jul 26, 2022 9:45am
BioNTech could owe CureVac $500M in royalties if suit succeeds
Jul 12, 2022 10:05am
